A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: Feasibility, tolerability and clinical outcomes

dc.contributor.authorLee, Nicole
dc.contributor.authorPennay, Amy
dc.contributor.authorHester, Robert
dc.contributor.authorMcKetin, Rebecca
dc.contributor.authorNielsen, Suzi
dc.contributor.authorFerris, Jason
dc.date.accessioned2015-12-10T21:53:52Z
dc.date.issued2013
dc.date.updated2016-02-24T10:33:29Z
dc.description.abstractIntroduction and Aims: There are no medications approved for the treatment of methamphetamine withdrawal. Wake-promoting agent modafinil has recently been proposed as a viable option. This paper reports on the results of a pilot study that tested the feasibility of modafinil in an inpatient withdrawal setting during acute methamphetamine withdrawal. Design and Methods: In a double-blind, randomised, placebo-controlled study, 19 methamphetamine dependent participants received modafinil (n=9) or placebo (n=10) daily for 7days (200mg for the first 5days and 100mg on days 6 and 7). Primary outcomes were retention in treatment and severity of withdrawal symptoms. Secondary outcomes were methamphetamine craving, sleep and physiological outcomes. Results: There were no significant differences between groups on retention in treatment, withdrawal severity, craving, sleep or physiological outcomes. There were no adverse events or side-effects reported. Conclusions: Modafinil was found to be tolerable and well accepted by methamphetamine users and feasible for short-term inpatient withdrawal, but the sample was too small to detect treatment effects. Larger trials are needed to establish efficacy.
dc.identifier.issn0959-5236
dc.identifier.urihttp://hdl.handle.net/1885/38691
dc.publisherCarfax Publishing, Taylor & Francis Group
dc.sourceDrug and Alcohol Review
dc.subjectKeywords: Methamphetamine; Modafinil; Randomised controlled trial; Withdrawal
dc.titleA pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: Feasibility, tolerability and clinical outcomes
dc.typeJournal article
local.bibliographicCitation.lastpage95
local.bibliographicCitation.startpage88
local.contributor.affiliationLee, Nicole, Flinders University
local.contributor.affiliationPennay, Amy, Curtin University
local.contributor.affiliationHester, Robert, University of Melbourne
local.contributor.affiliationMcKetin, Rebecca, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationNielsen, Suzi, Turning Point Alcohol and Drug Centre
local.contributor.affiliationFerris, Jason, Turning Point Alcohol and Drug Centre
local.contributor.authoremailu5065925@anu.edu.au
local.contributor.authoruidMcKetin, Rebecca, u5065925
local.description.embargo2037-12-31
local.description.notesImported from ARIES
local.identifier.absfor111714 - Mental Health
local.identifier.absseo970111 - Expanding Knowledge in the Medical and Health Sciences
local.identifier.ariespublicationu4056230xPUB165
local.identifier.citationvolume32
local.identifier.doi10.1111/j.1465-3362.2012.00473.x
local.identifier.scopusID2-s2.0-84872288283
local.identifier.thomsonID000313518300015
local.identifier.uidSubmittedByu4056230
local.type.statusPublished Version

Downloads

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
01_Lee_A_pilot_randomised_controlled_2013.pdf
Size:
271.65 KB
Format:
Adobe Portable Document Format
Back to topicon-arrow-up-solid
 
APRU
IARU
 
edX
Group of Eight Member

Acknowledgement of Country

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.


Contact ANUCopyrightDisclaimerPrivacyFreedom of Information

+61 2 6125 5111 The Australian National University, Canberra

TEQSA Provider ID: PRV12002 (Australian University) CRICOS Provider Code: 00120C ABN: 52 234 063 906